Chronic Proton Pump Inihibitor Therapy And Calcium Metabolism
Published 2012 · Medicine
Download PDFAnalyze on Scholarcy
Proton pump inhibitors (PPIs) have been widely used since their introduction in the late 1980s because they are highly effective for acid-related conditions. However, some recent epidemiological studies have suggested a positive association between PPI therapy and the risk of osteoporotic fractures. The potential mechanisms underlying this association may be related to the physiologic effects of chronic acid suppression on calcium metabolism. First, chronic hypergastrinemia induced by PPI therapy may lead to parathyroid hyperplasia, resulting in increased loss of calcium from the bone. Second, profound gastric acid suppression may reduce the bioavailability of calcium for intestinal absorption. I will review the published evidence regarding these potential links and discuss their clinical implications.
This paper references
Calcium and osteoporosis.
B. Nordin (1997)
Dietary intake of selected vitamins for the United States population: 1999-2000.
R. Ervin (2004)
Omeprazole in the long-term management of patients with acid-related diseases resistant to ranitidine.
G. Brunner (1989)
Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients.
D. Corley (2010)
Radiocalcium absorption is reduced in postmenopausal women with vertebral and most types of peripheral fractures
B. Nordin (2004)
Effect of long-term treatment with omeprazole on serum gastrin and serum group A and C pepsinogens in patients with reflux esophagitis.
J. B. Jansen (1990)
Factors influencing the measurement of bioavailability, taking calcium as a model.
R. Heaney (2001)
Effect of L-lactic acid on the absorption of calcium in gastrectomized rats.
O. Chonan (1998)
Long-term maintenance treatment of reflux esophagitis with omeprazole
H. Koop (1991)
Gastrointestinal absorption of calcium from milk and calcium salts.
M. Sheikh (1987)
Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study
S. Pouwels (2010)
Chicken Parathyroid Hormone Gene Expression in Response to Gastrin, Omeprazole, Ergocalciferol, and Restricted Food Intake
R. Gagnemo-Persson (1997)
Relationship between reduction of gastric acid secretion and plasma gastrin concentration during omeprazole treatment.
T. Lind (1988)
A model of lifetime osteoporosis impact.
E. Chrischilles (1991)
Low Fractional Calcium Absorption Increases the Risk for Hip Fracture in Women with Low Calcium Intake
K. Ensrud (2000)
Quantitative bone histomorphometry in humoral hypercalcemia of malignancy: uncoupling of bone cell activity.
A. F. Stewart (1982)
Pharmacokinetic and Pharmacodynamic Comparison of Two Calcium Supplements in Postmenopausal Women
H. Heller (2000)
The parathyroid glands in experimentally induced hypergastrinemia in the rat.
L. Grimelius (1977)
Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study
H. Khalili (2012)
Dietary supplement use by US adults: data from the National Health and Nutrition Examination Survey, 1999-2000.
K. Radimer (2004)
Long-term proton pump inhibitor therapy and risk of hip fracture.
Yu-Xiao Yang (2006)
Acid-Suppressive Medications and Risk of Bone Loss and Fracture in Older Adults
E. Yu (2008)
Session 5: Trophic Effects of Gastrin
R. Håkanson (1991)
Long-term omeprazole treatment suppresses body weight gain and bone mineralization in young male rats.
G. Cui (2001)
Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial.
M. B. O'Connell (2005)
Meal effects on calcium absorption.
R. Heaney (1989)
The absorption of calcium carbonate.
P. Ivanovich (1967)
Regulation of vitamin D and calcium metabolism after gastrectomy.
L. Nilas (1985)
Calcium absorption and achlorhydria.
R. Recker (1985)
An evaluation of the importance of gastric acid secretion in the absorption of dietary calcium.
G. Bo-Linn (1984)
Do Proton Pump Inhibitors Decrease Calcium Absorption?
K. Hansen (2010)
Growth of the parathyroid glands in omeprazole-treated chickens.
R. Gagnemo-Persson (1994)
Proton Pump Inhibitors, Histamine H2 Receptor Antagonists, and Other Antacid Medications and the Risk of Fracture
P. Vestergaard (2006)
Effect of omeprazole, an inhibitor of H+, K+-ATPase, on bone resorption in humans
K. Mizunashi (2005)
Low gastric hydrochloric acid secretion and mineral bioavailability.
E. Champagne (1989)
Proton pump inhibitor use and risk of hip fractures in patients without major risk factors.
J. Kaye (2008)
Inhibition of gastric secretion by omeprazole and efficiency of calcium carbonate on the control of hyperphosphatemia in patients on chronic hemodialysis.
P. Hardy (1998)
Mortality, disability, and nursing home use for persons with and without hip fracture: a population-based study.
C. Leibson (2002)
Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease
K. Devault (1999)
Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis.
R. Lamberts (1993)
Processing and proliferative effects of human progastrin in transgenic mice.
T. Wang (1996)
Effect of gastric acid secretion on intestinal phosphate and calcium absorption in normal subjects.
G. Graziani (1995)
Updated Guidelines for the Diagnosis and Treatment of Gastroesophageal Reflux Disease
K. Devault (2005)
Persistence, reproducibility, and cost-effectiveness of an intervention to improve the quality of osteoporosis care after a fracture of the wrist: results of a controlled trial
S. Majumdar (2006)
Calcium and Phosphate Plasma Levels in Dialysis Patients after Dietary Ca-P Overload
G. Graziani (2002)
Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative.
S. Gray (2010)
Therapy with omeprazole in patients with peptic ulcerations resistant to extended high-dose ranitidine treatment.
G. Brunner (1988)
Trends in prescribing H2‐receptor antagonists and proton pump inhibitors in primary care
Why are patients prescribed proton pump inhibitors? Retrospective analysis of link between morbidity and prescribing in the General Practice Research Database
J. Bashford (1998)
Use of proton pump inhibitors and risk of osteoporosis-related fractures
L. Targownik (2008)
Effect of L-lactic acid on calcium absorption in rats fed omeprazole.
O. Chonan (1998)
Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis
R. Lindsay (1997)
Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone.
R. Jilka (1999)
Serum gastrin levels during long‐term omeprazole treatment
H. Koop (1990)
Hypochlorhydria from short-term omeprazole treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesium or zinc from food in humans.
C. Serfaty-Lacrosniere (1995)
Controlled clinical trials of omeprazole in the long-term management of reflux disease.
D. Hetzel (1992)
This paper is referenced by
Crystal structure and bonding analysis of the first dinuclear calcium(II)-proton-pump inhibitor (PPI) `butterfly molecule': a combined microcrystal synchrotron and DFT study.
Hengjiang Cong (2016)
Effects of long-term administration of pantoprazole on bone mineral density in young male rats.
Agnieszka Matuszewska (2016)
Medical Treatment of GERD
C. Muller (2020)
Effects of Non-Steroidal Anti-Inflammatory Drugs on the Gastrointestinal and Cardiovascular System
G Masclee (2016)
Medications and Micronutrients: Identifying Clinically Relevant Interactions and Addressing Nutritional Needs
Jeffery David Prescott (2018)
Effects of long-term administration of omeprazole on bone mineral density and the mechanical properties of the bone☆
G. Yanagihara (2015)
Nonpharmacological interventions for osteoporosis treatment: Systematic review of clinical practice guidelines
Roberto Coronado-Zarco (2019)
Medical Management of LPR
Justin Field (2019)
Pharmacological reports about gastroprotective effects of methanolic extract from leaves of Solidago chilensis (Brazilian arnica) and its components quercitrin and afzelin in rodents
Mariel de Barros (2015)
A Benefit–Risk Assessment of the Use of Proton Pump Inhibitors in the Elderly
G. Masclee (2014)
Causes of emergency department visits following thyroid and parathyroid surgery.
W. Young (2013)
Refractory hypocalcemia and hypomagnesemia associated with the use of an oral proton-pump inhibitor in a patient with hypoparathyroidism
Yea-Shin Lin (2015)
Mandibular Implant Prostheses
E. Emami (2018)
Omeprazole Reduces Calcium Digestibility in Thoroughbred Horses.
Joe D. Pagan (2020)
Proton Pump Inhibitors and Fracture Risk: A Review of Current Evidence and Mechanisms Involved
Benjamin Ka Seng Thong (2019)
Gastro-Esophageal Reflux in Neonatology
Keith Barrington (2013)
Analysis of fracture healing in osteopenic bone caused by disuse: experimental study
A G Paiva (2016)
Effect of GutsyGumtm, A Novel Gum, on Subjective Ratings of Gastro Esophageal Reflux Following A Refluxogenic Meal
R. Brown (2015)
Drug-induced osteoporosis: from Fuller Albright to aromatase inhibitors
D V Byreddy (2015)
Efeitos da administração em longo prazo do omeprazol sobre a densidade mineral óssea e as propriedades mecânicas do osso
G. Yanagihara (2015)
Osteopetrorickets due to Snx10 Deficiency in Mice Results from Both Failed Osteoclast Activity and Loss of Gastric Acid-Dependent Calcium Absorption
L. Ye (2015)
Use of proton pump inhibitors is associated with lower trabecular bone density in older individuals.
M. Maggio (2013)
Early Acid Suppression Therapy Exposure and Fracture in Young Children
Laura Malchodi (2019)
Proton pump inhibitor use and risk of hip fracture in patients with type 2 diabetes
Ya-Shuan Chou (2020)
Esomeprazole use is independently associated with significant reduction of BMD: 1-year prospective comparative safety study of four proton pump inhibitors
E. Bahtiri (2015)
Nutrition for the Preterm Neonate
S. Patole (2013)
Systemic administration of omeprazole interferes with bone healing and implant osseointegration: an in vivo study on rat tibiae.
Ahmed Al Subaie (2016)
Proton Pump Inhibitors and Osteoporosis: Is Collagen a Direct Target?
Y. Ghebre (2020)
The Evaluation of omeprazole effect on the sensitivity of 99mTc-MDP bone-seeking to detect simulated closed fracture in the rat’s foot
A. Doroudi (2017)
Optimizing the Use of Medications and Other Therapies in Infant Gastroesophageal Reflux
Steven L. Ciciora (2018)
Proton pump inhibitor use and fracture risk - effect modification by histamine H1 receptor blockade. Observational case-control study using National Prescription Data.
B. Abrahamsen (2013)
A review of lifestyle, smoking and other modifiable risk factors for osteoporotic fractures.
B. Abrahamsen (2014)See more